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Abstract
Background: Bleeding represents the most well-known and the most feared complications caused by the use of
antithrombotic agents. There is, however, limited documentation whether pre-injury use of antithrombotic agents
affects outcome after head trauma. The aim of this study was to define the relationship between the use of
preinjury antithrombotic agents and mortality among elderly people sustaining blunt head trauma.
Methods: A retrospective cohort analysis was performed on the hospital based trauma registry at Oslo University
Hospital. Patients aged 55 years or older sustaining blunt head trauma between 2004 and 2006 were included.
Multivariable logistic regression analyses were used to identify independent predictors of 30-day mortality.
Separate analyses were performed for warfarin use and platelet inhibitor use.
Results: Of the 418 patients admitted with a diagnosis of head trauma, 137 (32.8 %) used pre-injury antithrombotic
agents (53 warfarin, 80 platelet inhibitors, and 4 both). Seventy patients died (16.7 %); 15 (28.3 %) of the warfarin users,
12 (15.0 %) of the platelet inhibitor users, and two (50 %) with combined use of warfarin and platelet inhibitors,
compared to 41 (14.6 %) of the non-users. There was a significant interaction effect between warfarin use and the
Triage Revised Trauma Score collected upon the patients’ arrival at the hospital. After adjusting for potential confounders,
warfarin use was associated with increased 30-day mortality among patients with normal physiology (adjusted OR
8,3; 95 % CI, 2.0 to 34.8) on admission, but not among patients with physiological derangement on admission.
Use of platelet inhibitors was not associated with increased mortality.
Conclusions: The use of warfarin before trauma was associated with increased 30-day mortality among a subset
of patients. Use of platelet inhibitors before trauma was not associated with increased mortality. These results indicate
that patients on preinjury warfarin may need closer monitoring and follow up after trauma despite normal physiology
on admission to the emergency department.
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Background
Bleeding, particularly intracranial bleeding, represents
the most well-known and the most feared complica-
tions with use of antithrombotic agents, and is associ-
ated with a high morbidity and mortality. There is,
however, limited documentation whether pre-injury use
of antithrombotic agents affects mortality after blunt
head trauma. A number of studies have described an
increased risk of mortality in head trauma patients on
preinjury warfarin [1–5], while other studies report no
difference in outcome [6–9]. Studies on outcome after
head trauma vary with respect to study design, outcome
measurements, and patient characteristics, making
comparisons between studies difficult. Most of the pre-
vious studies are small (less than 40 individuals using
warfarin). Larger studies from administrative- and trauma
databases have shown an increased risk of mortality in
trauma patients on preinjury warfarin [10–12]. The evi-
dence is conflicting, however, as no increased mortality
was seen among subpopulations such as patients 65 years
and older with intracranial haemorrhage [10] or among
patients with head injury [11]. In some studies, the thera-
peutic anticoagulation, not the warfarin use itself, has
been shown to be important [4, 13–15], indicating that
anticoagulants may play a mechanistic role in the adverse
outcomes and not serve as markers for co-morbidity that
leads to worse outcome.
Whether preinjury use of platelet inhibitors affects
mortality after head trauma is even less well studied,
and results are conflicting [2, 16–18]. Therefore, fur-
ther studies exploring the association between preinjury
use of antithrombotic agents and trauma outcome are
of critical importance.
The objective of this study was to define the relation-
ship between preinjury use of antithrombotic agents
and mortality among elderly patients sustaining head
trauma.
Methods
Oslo University Hospital Ulleval (OUH-U) is the
major trauma hospital for 550 000 citizens and the
trauma referral centre for 2.5 million people. Annu-
ally, approximately 1 000 patients of all age groups
admitted to OUH-U within 24 h after trauma are reg-
istered in the hospital-based trauma registry (Oslo
University Hospital Trauma Registry). In this cohort
study, patients 55 years or older with blunt head
trauma (documented by a diagnosis of concussion,
skull laceration or more serious head trauma) were in-
cluded. Exclusion criteria were penetrating skull injury
and intracranial bleeding before trauma. The study in-
clusion period was 1 January 2004 to 31 December
2006. Death within 30 days after trauma was the pri-
mary outcome. Use of antithrombotic agents was the
primary exposure of interest. Two separate logistic re-
gression analyses were performed to assess risk factors
of mortality among warfarin users and platelet inhibi-
tors users, respectively.
Preinjury use of warfarin, acetylsalicylic acid (ASA), or
clopidogrel, as well as the degree of anticoagulation (i.e.,
International Normalised Ratio, INR) was determined by
a review of electronic medical records. No description of
antithrombotic agents was considered as non-use. An
INR of ≥ 2.0 was considered as therapeutic. Thirty-day
mortality was used as main outcome instead of in-
hospital mortality because in-hospital mortality can be
influenced by early discharge or transfers to other hospi-
tals [19]. The variables assessed as potential confounders
on the relationship between antithrombotic drug use
and 30-day mortality risk included: age, gender, high- vs
low-energy trauma, anatomic injury severity (New Injury
Severity Score, NISS), physiological derangement on
admission (Triage Revised Trauma Score, T-RTS), and
co-morbidity (American Society of Anaesthesiologists
Physical Status, ASA-PS). High-energy trauma was de-
fined as motor vehicle and bicycle accidents. Low-
energy trauma was defined as falls and other trauma
mechanisms. The ASA-PS classification system reflects
the co-morbidity existing before the trauma; ASA-PS 1:
healthy person, ASA-PS 2: mild systemic disease, ASA-
PS 3: severe systemic disease, and ASA-PS 4: severe
systemic disease that is a constant threat to life [20].
The variables NISS, T-RTS and ASA-PS have been
shown to be independent predictors of survival after
trauma [21, 22]. NISS has been shown to be a more ac-
curate method for rating patients with multiple serious
injuries in a single body region, e.g., traumatic brain
injury, and was thus used instead of the Injury Severity
Score (ISS) in the statistical analyses [21, 22]. The T-
RTS (range 0–12) is defined as the sum of the clinical
category values of respiratory rate (RR), systolic blood
pressure (SBT) and Glasgow Coma Scale (GCS), all
range 0–4 [22]. Normal physiology was defined as T-
RTS = 12, physiological derangement as T-RTS ≤ 11.
The T-RTS was used since it has been shown to be a
better predictor of outcome than one or more of GCS,
RR, and SBP. The variables were collected upon the pa-
tients’ arrival at the hospital, but pre-hospital GCS, RR,
and SBP scores were used to score T-RTS when in-
hospital values were unobtainable.
Ethics
The Regional Committee for Medical Research Ethics and
the Privacy Protection Ombudsman at Oslo University
Hospital approved the study. Since data was analysed
anonymized, informed consent was waived by the Re-
gional Committee for Medical Research Ethics.
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Statistical analysis
Normally distributed variables were expressed as means
± SD and compared using the student’s t-test. The asso-
ciation between patient anticoagulant use and injury
characteristics, and outcome (30-day mortality), was
assessed using univariate logistic regression with odds
ratios (OR) and 95 % confidence intervals (CI) calcu-
lated. The analysis was stratified according to warfarin
or platelet inhibitor use and checked for confounders
and interaction effects. Factors significantly associated
with mortality in the univariate analysis were thereby en-
tered into a multivariate stepwise logistic regression. All
analyses were performed using the Statistical Package
for the Social Sciences (SPSS) for Windows (version 20).
For all statistical tests, a p-value < 0.05 was considered
significant.
Results
A total of 431 patients aged 55 years or older, admitted
to OUH-U within 24 h of trauma during January 2004
to 31 December 2006, were identified. Thirteen patients
with penetrating skull injury or with suspected intracra-
nial bleeding before trauma were excluded. This left 418
patients for analysis, 254 (60.8 %) male and 164 (39.2 %)
female. The age was normally distributed with mean age
71.4 years. Totally, 156 (37.3 %) patients were defined as
having severe preinjury co-morbidity (ASA-PS 3 or 4).
In 326 patients (78.0 %), anatomic injury was defined as
major trauma (NISS ≥ 15), whereas physiological de-
rangement (T-RTS ≤ 11) was present in 162 patients
(38.8 %). Seventy patients (16.7 %) died within 30 days
after injury. The 30-day mortality was 23 % (27/116) in
2004, compared to 14 % in 2005 (22/152) and 14 % in
2006 (21/150) (p = 0.085). The patients who survived
were significantly different from patients who died with
respect to age, warfarin use, preinjury morbidity, NISS,
ISS, T-RTS, and INR, as shown in Table 1. Falls (257;
61.5 %) and motor vehicle accidents (110; 26.3 %) were
the most common trauma mechanisms (Table 2).
Of the 137 (32.8 %) patients using antithrombotic
agents, 53 used warfarin, 80 used platelet inhibitors (73
ASA, 3 clopidogrel, 4 both), and 4 patients used both
warfarin and platelet inhibitors (2 warfarin/ASA, 1 war-
farin /clopidogrel, 1 warfarin / both). The corresponding
30-day mortality according to clinical characteristics is
shown in Table 1. Table 2 shows demographics and
trauma mechanisms according to exposure status. The
warfarin and the platelet inhibitor users (mean age 76.6
and 76.0 years, respectively) were significantly older than
the non-users (69.1 years) (p < 0.001 for both) and had
higher preinjury morbidity (mean ASA-PS 2.81 and 2.58,
respectively) compared to the non-users (ASA-PS 1.84,
both p < 0.001). The primary indications for warfarin use
were atrial fibrillation in 25 patients, cardiac valve
replacement in 13 patients, previous deep vein throm-
bosis/lung embolism in 6 patients, and myocardial in-
farction in 2 patients.
Separate logistic regression analyses were performed
to evaluate the effect of warfarin and platelet inhibitors
on 30-day mortality. The four patients who used both
warfarin and platelet inhibitors were excluded from the
analyses.
Preinjury warfarin use was a significant predictor of
30-day mortality in the univariate logistic regression
analysis, together with older age, anatomic severity
(higher NISS), physiological derangement (lower T-
RTS) on admission, and pre-injury co-morbidity (higher
ASA-PS). Gender and trauma mechanism did not affect
the outcome. There was a significant interaction effect
between warfarin and T-RTS, suggesting that among
patients with physiological derangement (T-RTS ≤ 11)
on admission, mortality was to a lesser degree predicted
by warfarin (Table 3). In the multivariate logistic model
(Table 4), ORs for predictors of 30-day mortality are
presented separately for patients with normal physi-
ology (T-RTS = 12) and patients with physiological de-
rangement (T-RTS ≤ 11).
For patients with T-RTS ≤ 11 on admission, the un-
adjusted mortality was 35.0 % (7/20) and 31.9 % (37/
116) among patients on warfarin and patients on no an-
tithrombotic agents, respectively. Among patients with
Table 1 Demographics and clinical characteristics for 418
patients according to outcome
Dead Alive P value
Male (%) 39 (15.4) 215 (84.6) 0.343
Female 31 (18.9) 133 (81.1)
Age mean (SD) 75.8 (10.4) 70.6 (10.4) 0.019
No anticoagulant use (%) 41 (14.6) 240 (85.4) Default
- Warfarin 15 (28.3) 38 (71.7) 0.014
- Platelet inhibitors 12 (15.0) 68 (85.0) 0.927
- Warfarin and platelet inhibitors 2 (50.0) 2 (50.0) 0.049
High energy trauma 20 (14.4) 119 (85.6) 0.28
Low energy trauma 48 (18.7) 209 (81.3)
Other mechanisms/unknown 2 (9.1) 20 (90.9) 0.51
ASA-PS mean (SD)a 2.4 (1.0) 2.1 (0.9) 0.001
NISS mean (SD) 46.2 (15.7) 25.4 (14.7) < 0.001
ISS mean (SD) 26.7 (9.5) 18.0 (9.7) < 0.001
T-RTS mean (SD) 9.5 (2.0) 11.3 (1.3) < 0.001
INR > 3.5 3 (18.8) 13 (81.3) < 0.001
INR 2.0–3.5 14 (45.2) 17 (54.8)
INR < 2.0 20 (20.8) 76 (79.2)
INR not done 33 (12.0) 242 (88.0)
ICU days median (IQR) 1.5 (1.0–4.0) 2.0 (1.0–6.0) 0.921
aASA-PS classification was missing for 2 patients
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normal physiology on admission, use of warfarin in-
creased the mortality eight times, as 25.0 % (8/32) of
patients on warfarin died compared to 2.4 % (4/165) of
patients on no antithrombotic agents. Very similar re-
sults were found when INR was included in the regres-
sion analysis instead of warfarin (results not shown).
There was an interaction between therapeutic INR and
T-RTS, with 29.0 % mortality among patients with INR
≥ 2.0 and normal physiology compared to only 2.9 %
mortality among patients with INR < 2.0.
Preinjury platelet inhibitor use was not a significant
predictor of 30-day mortality in the univariate logistic
regression analysis. In the multivariate logistic model
(Table 4), significant predictors of mortality for preinjury
Table 2 Sample characteristics by exposure status
No anticoagulants Warfarin only ASA/clopidogrel only Both warfarin and ASA/clopidogrel
Sample size, n (%) 281 (67.2) 53 (12.7) 80 (19.1) 4 (1.0)
Age mean (SD) 69.1 (10.2) 76.3 (9.7) 76.0 (10.0) 80.8 (5.6)
Gender, male (%) 167 (59.4) 39 (73.6) 45 (56.3) 3 (75.0)
Gender, female (%) 114 (40.6) 14 (26.4) 35 (43.8) 1 (25)
ASA-PS (%)a
1 113 (40.2) 4 (7.5) 8 (10) 0
2 105 (37.4) 9 (17.0) 21 (26.3) 0
3 or 4 61 (21.7) 40 (75.5) 51 (63.7) 4 (100)
ISS mean (SD) 19.6 (11.2) 20.6 (5.8) 18.4 (8.6) 22.0 (14.1)
NISS mean (SD) 28.5 (17.2) 30.4 (13.6) 28.3 (15.9) 42.2 (34.3)
RTS median (quartiles) 12.0 (10.0–12.0) 12.0 (10.0–12.0) 12.0 (11.0–12.0) 9.5 (8.25–11.5)
INR ≥ 2.0 (%) 5 (1.8) 39 (74.0) 0 3 (75.0)
INR < 2.0 (%) 60 (21.4) 11 (20.8) 24 (30.0) 1 (25.0)
INR not done (%) 216 (76.9) 3 (5.7) 56 (70.0) 0
30-day mortality (%) 41 (14.6) 15 (28.3) 12 (15.0) 2 (50)
Trauma mechanism (%)
Motor vehicle accidents 83 (29.5) 7 (13.2) 19 (23.8) 1 (25.0)
Bicycle accidents 23 (8.2) 3 (5.7) 3 (3.8) 0
Falls 159 (56.6) 41 (77.4) 54 (67.5) 3 (75.0)
Other mechanisms 13 (4.6) 1 (1.9) 3 (3.8) 0
Unknown 3 (1.1) 1 (1.9) 1 (1.3)
Falls (%)
Fall out of bed 3 (1.9) 2 (4.9) 3 (5.6) 0
Fall from standing 71 (44.7) 28 (68.3) 30 (55.6) 1 (33.3)
Fall in stairs 41 (25.8) 8 (19.5) 11 (20.4) 1 (33.3)
Fall from heights 37 (23.3) 2 (4.9) 8 (14.8) 0
Other falls 7 (4.4) 1 (2.4) 2 (3.7) 1 (33.3)
aASA-PS classification was missing for 2 patients
Table 3 Warfarin and effect of confounding
Dead Dead Alive Alive
Warf No warf Warf No warf OR (95 %) OR MH (95 %) Breslow-Day Inter-action
Crude 15 41 38 240 2.311 (1.167, 4.576)
T-RTS X 0.002
12 8 4 24 161 13.417 (3.751, 47.992)
11 or less 7 37 13 79 1.150 (0.424, 3.120)
Warf warfarin, OR odds ratio, MH Mantel Haenzel
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platelet inhibitor users were older age, anatomic sever-
ity (higher NISS), and physiological derangement (lower
T-RTS).
Discussion
Outcome after head trauma may be affected by injury
mechanisms, patient characteristics, quality of care, and
potentially interactions between them. Our study sup-
ports previous studies reporting that preinjury use of
warfarin, but not platelet inhibitors, are associated with
increased mortality following head trauma. In addition,
our study indicates that the effect of warfarin on mortal-
ity might be dependent on physiological status. Among
patients with normal physiology on admission (T-RTS =
12), warfarin use was associated with increased risk of
mortality compared to use of no anticoagulants (25 % vs
2 %, respectively). Among patients with physiological
derangement (T-RTS ≤ 11) on admission, in contrast,
equally high risk of mortality was found among patients
with preinjury use of warfarin and those who did not
use anticoagulants (35 % vs 32 %, respectively). It thus
seems like the negative impact of preinjury warfarin use
on mortality is most pronounced in a subpopulation of
patients with severe trauma and with normal physiology
on admission. Trauma care providers should be aware of
this increased mortality risk among head trauma patients
on warfarin presenting with normal physiology. Our re-
sult is in accordance with a retrospective review includ-
ing patients with fall from standing [23], and a more
recently published study on outcome after head trauma
in Medicare beneficiaries [24].
Two recently published large cohort studies, in contrast,
showed no increased mortality risk in subpopulations of
warfarin users 65 years and older with intracranial haem-
orrhage [10] or among patients with head injury [11].
Those studies, however, included patients with an ex-
pected lower mortality risk, such as younger patients and
patients with non-head traumas.
Preinjury morbidity has been shown to be an inde-
pendent predictor of mortality in the NORMIT model
[20, 22]. Surprisingly, co-morbidity (ASA-PS) was not
independently associated with mortality in our analysis,
and we did not find any interaction effect between NISS
and co-morbidity. In our study, more than one third of
the patients were classified as having severe systemic
disease (ASA-PS 3 or 4), in contrast to 10 % with severe
Table 4 Logistic regression models
Crude Adjusted
OR (95 % CI) P value OR (95 % CI) P value
Warfarin with normal physiology (T-RTS = 12)
Age 1.138 (1.062, 1.219) < 0.001 1.125 (1.040, 1.216) 0.003
Gender 0.785 (0.228, 2.701) 0.701
Warfarin 13.417 (3.751, 47.992) < 0.001 8.278 (1.969, 34.794) 0.004
Trauma mechanism 0.500 (0.131, 1.908) 0.310
ASA-PS 3.707 (1.630, 8.428) 0.002
NISS 1.088 (1.028, 1.153) 0.004 1.088 (1.014, 1.168) 0.019
Warfarin with physiological derangement (T-RTS≤ 11)
Age 1.066 (1.024, 1.110) 0.002 1.090 (1.039, 1.143) < 0.001
Gender 1.887 (0.905, 3.934) 0.090
Warfarin 1.150 (0.424, 3.120) 0.784
Trauma mechanism 1.065 (0.483, 2.347) 0.877
ASA-PS 1.257 (0.862, 1.833) 0.234
NISS 1.056 (1.028, 1.084) < 0.001 1.064 (1.035, 1.095) < 0.001
Platelet inhibitors
Age 1.036 (1.008, 1.064) 0.010 1.081 (1.039, 1.123) < 0.001
Gender 1.583 (0.882, 2.842) 0.124
Platelet inhibitors 1.033 (0.514, 2.075) 0.927
Trauma mechanism 0.838 (0.450, 1.561) 0.578
ASA-PS 1.304 (0.927, 1.834) 0.128
NISS 1.089 (1.065, 1.114) < 0.001 1.070 (1.042, 1.097) < 0.001
T-RTS 0.483 (0.396, 0.590) < 0.001 0.582 (0.453, 0.749) < 0.001
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systemic disease found in the study by Jones et al. Differ-
ences in study populations may explain the lack of effect
of co-morbidity on mortality in our study.
Use of platelet inhibitors was not associated with in-
creased mortality. Studies of antiplatelet use and out-
come after head trauma are sparse, the studies are small
and results are conflicting [2, 7, 12, 17, 25, 26]. The ex-
planation for this lack of knowledge is complex, but
main reasons are lack of information of antiplatelet use
in the patient administrative databases, use of over-the-
counter platelet inhibitors and use of drugs with platelet
inhibition as a pleiotropic effect. The difficulty in assess-
ment of platelet activity through laboratory tests, and
the assumption of a smaller bleeding risk compared to
warfarin use as seen in other settings, may contribute to
the lack of knowledge. This indicates a smaller effect (if
any) of platelet inhibition on outcome after head trauma
compared to warfarin use.
The strengths of this present study include informa-
tion regarding the assessment of preinjury morbidity, de-
scription of trauma mechanisms, severity of the injury,
and the degree of anticoagulation among the majority of
the anti-coagulated patients. In studies on trauma out-
come, several outcome measures are used such as in-
hospital mortality, mortality by end of somatic care, and
mortality at 30 days after trauma. We used 30-day mor-
tality since this has been validated in the currently used
trauma databank, and has been shown to be the best
outcome measure after blunt trauma [19]. Patients intu-
bated before hospital arrival have often been excluded
from studies due to lack of T-RTS data. In the OUH-U
Trauma Registry the GCS and RR scores recorded be-
fore intubation could also be used to include patients
intubated before arrival. This means that no group is
systematically excluded in this analysis. This study has
a retrospective cohort design. Other head-trauma stud-
ies, in contrast, have used (matched) case control de-
sign [2, 6, 9]. Both study types, with their advantages
and disadvantages, may be used to explore the relation-
ship between warfarin use, head trauma and mortality.
If warfarin causes more intracranial bleeding, adjust-
ment for injury severity in a matched case control de-
sign may cause the differences to disappear because the
scoring of anatomic severity accounts for the size of
intracranial hematomas.
The main limitation of this study is the retrospective
design, which precludes the ability to establish a causal
relationship between the risk factors and the outcome.
Likewise, there is a possibility of sampling biases if pa-
tients on antithrombotic agents or with supra-therapeutic
INR are less likely to be transferred from the local hospital
to the trauma referral centre due to more severe head in-
jury with prospected poor outcome. A lower mortality
among patients with supra-therapeutic INR compared to
patients with INR in the therapeutic range may indicate a
sampling bias, which would make us underestimate the
true mortality risk with antithrombotic agents. An asso-
ciation between the degree of anticoagulation and mor-
tality has been found in some studies of outcome after
trauma [4, 13], but not in other studies [7, 8]. This may
be explained by a high (almost 50 %) occurrence of
sub-therapeutic INR at the time of trauma in these
studies [7, 8]. Trauma-induced coagulopathy in patients
with severe trauma has been associated with increased
mortality, and the incidence of coagulation disorders
and subsequent mortality has been particularly high fol-
lowing traumatic brain injury [27]. In our study, we do
not know if the non-users of warfarin with therapeutic
INR had trauma-induced coagulopathy or were undis-
closed warfarin users, or if the warfarin users had
trauma-induced coagulopathy in addition to the war-
farin induced coagulopathy. Further, we had no access
to descriptions of intracranial pathology or cause of
death. Such descriptions would have provided deeper
insight into trauma severity, however, intracranial path-
ology is at least partly accounted for in the anatomic
trauma score (NISS). Another limitation is the sample
size. Despite OUH-U is a trauma referral centre for 2.5
million people, only 418 patients with blunt head
trauma of 55 years or older fitted the inclusion criteria
during a three year period. The small sample size may
thus contribute to uncertain estimates as seen by the
wide confidence intervals. This is also a single-centre
review whose findings may not be applicable to other
centres. In these data, the relationship between use of
warfarin and increased mortality persisted after control-
ling for covariates available in the trauma databank.
Whether there are other unmeasured confounders that
account for these findings rather than therapeutic anticoa-
gulation, is unknown.
Assessment of preinjury use of warfarin or platelet
inhibitors was based on information in the patient re-
cords. Thus, underreporting or misclassification may
exist. The misclassification is probably larger for the
platelet inhibitor use, since there was no assessment of
platelet activity. Use of additional drugs affecting plate-
lets, such as nonsteroidal anti-inflammatory drugs,
serotonin transporter or receptor inhibitors, or over-the
counter ASA, was sparsely reported in the patient re-
cords and may explain the lack of effects of platelet in-
hibitors on mortality.
Conclusions
In conclusion, our data suggest that use of warfarin is
associated with an increased 30-day mortality following
blunt head trauma among the subset of patients with
normal physiology at admission. Among patients with
physiological derangement at admission, about a third of
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all patients died independently of warfarin use. In con-
trast, the use of platelet inhibitors is not associated with
increased mortality. The result may indicate that pa-
tients with severe trauma and preinjury use of warfarin
need closer monitoring and follow up after trauma des-
pite normal physiology on admission.
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